C4 Therapeutics posts Phase 1 cemsidomide data in RRMM; terminates TD Cowen ATM prospectus

C4 Therapeutics, Inc.

Posted Phase 1 data for cemsidomide + dex in relapsed/refractory multiple myeloma; presentation on IR website.
Terminated sales agreement prospectus with TD Cowen effective Oct 16, 2025; underlying agreement remains in effect.
Previously issued 3,769,483 shares under TD Cowen ATM for gross proceeds of $9.6M as of June 30, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.